newsfilter
← Latest News
Business Wire·

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced that Chairman and